content_top
43 companies, 1 interpreter! Insight, foresight
and recommendation 

Capricor (CAPR)

1.02
-0.01
(-0.97%)
Sep 11, 4:00PM EDT
content_middle

Capricor Therapeutics (OTCQB: CAPR) is focused on the advancement of stem cell-based therapies for prevention and treatment of heart damage associated with cardiac failure.  CAPR’s allogeneic cardiac-derived cells (CDCs) aim to attenuate and potentially improve damage to the heart that can result in heart failure, while Cenderitide, a novel peptide, is intended to treat patients following hospital discharge from an acute episode of heart failure. ALLSTAR, CAPR’s Allogeneic Heart Stem Cells to achieve myocardial regeneration trial began enrolling in late 2012.  

Previous Close: 
1.03
Open: 
1.00
Bid: 
1.00
Ask: 
1.05
1yr Target Price: 
2.15
Day's Range: 
1.00 - 1.03
52wk Range: 
0.63 - 4.00
Volume: 
42426
Average Daily Volume: 
1353650
Market Capitalization: 
23.05M
Trailing Annual Dividend Yield: 
N/A
Shares Outstanding: 
22595000M
content_right

Pages